All the Active Ingredient Drugs
Antiplatelet Agent. Ticagrelor 60 mg, 90 mg. F.C. TABS: 56. Pts. taking Ticagrelor should also take ASA dly., unless specific. contraind.
Follow. an init. dose of ASA, Ticagrelor should be used with a mainten. dose of ASA of 75-150 mg.
Acute coron. syndr.: Ticagrelor tmt. should be initi. with a single 180 mg load. dose (2 tabs. of 90 mg) and then contin. at 90 mg ×2/d.
Tmt. with Ticagrelor 90 mg ×2/d is recomm. for up to 12 mnths. in ACS pts. unless discont. is clinic. indic.
Ticagrelor 60 mg ×2/d dly. is the recomm. dose when an extend. tmt. is requir. for pts. with a hist. of MI of at least 1 year and a high risk of an atherothrombot. event. Tmt. may be started without interrupt. as contin. ther. after the init. 1 -year tmt. with Ticagrelor 90 mg or other adenosine diphosphate (ADP) recept. inhib. ther. in ACS pts. with a high risk of an atherothrombot. event. Tmt. can also be init. up to 2 yrs. from the MI, or within 1 year after stop. prev. ADP recept. inhibit. tmt.
In pts. with ACS, premat. discont. with any antiplat. ther., includ. Ticagrelor, could result in an incr. risk of cardiovasc. death, or MI due to the pt’s. underlying dis. Therefore, premature discont. of tmt. should be avoided. See lit.
Indic. co-admin. with ASA, is for the preven. of atherothrombot. events in adult pts. with - acute coron. syndr. (ACS) or - a hist. of MI and a high risk of develop. an atherothrombot.
Limitations of use: 90 mg ×2/d during the 1st year after an ACS event follow. by 60 mg ×2/d for addit. 2 yrs.
C/I: Hypersens. Active pathology. bleed. History of intracran. haemorr. Severe hep. impair. Co-admin. with strong CYP3A4 inhib. (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).